Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 412.82% from the stock’s previous close.

Separately, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday, August 13th.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $3.90 on Thursday. The business’s fifty day moving average price is $3.25 and its 200 day moving average price is $4.11. The firm has a market capitalization of $21.18 million, a PE ratio of -1.17 and a beta of 1.03. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Equities research analysts expect that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Marc Duey bought 30,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was purchased at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the acquisition, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Marc Duey bought 30,000 shares of the stock in a transaction on Wednesday, October 16th. The shares were purchased at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the acquisition, the director now owns 240,113 shares in the company, valued at $1,054,096.07. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 41,790 shares of company stock worth $163,136 in the last three months. Corporate insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.